FDCP
REGN icon

Foster Dykema Cabot & Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87K Hold
3
– – ﹤0.01% 303
2026
Q1 		$2.32K Hold
3
– – ﹤0.01% 296
2025
Q4 		$2.32K Buy
+3
New +$2.04K ﹤0.01% 304

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Foster Dykema Cabot & Partners's REGN Position: Q2 2026 in Review

Foster Dykema Cabot & Partners held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 3 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #303.

Foster Dykema Cabot & Partners first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.32K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Foster Dykema Cabot & Partners held 3 shares of Regeneron Pharmaceuticals worth $1.87K as of Q2 2026.
  • Foster Dykema Cabot & Partners left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Foster Dykema Cabot & Partners's portfolio in Q2 2026, its #303 holding.
  • Foster Dykema Cabot & Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Foster Dykema Cabot & Partners's Regeneron Pharmaceuticals position peaked at $2.32K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q2 2026, filed 11 Aug 2026.